CD8A and myeloid sarcoma: Five MS patients treated with teriflunomide exhibited a continuous increase in PD-1 expression on MOG-specific CD8+ TEM after 2- and 4-weeks therapy (Figure 4D), while the expression of the remaining cytokines or co-stimulatory molecules presented slight or irregular changes (Figures 4A-C, E-J).